You are here: Industry Insights > Opdivo

News List

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma En-CPhI.CN
November 13, 2019
The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication.
Bristol-Myers Squibb's Opdivo fails 3rd straight test in tough-to-treat brain cancer fiercepharma
September 08, 2019
Bristol-Myers Squibb has once again come up empty-handed in one of the world’s deadliest and toughest-to-treat cancers.
Bristol-Myers Squibb Announces Opdivo Glioblastoma Study Does Not Meet PFS Primary Endpoint americanpharmaceuticalreview
September 06, 2019
Bristol-Myers Squibb announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard ...
Nektar Therapeutics, BMS Receive Breakthrough Therapy Designation contractpharma
August 02, 2019
Bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo aims to treat patients with untreated advanced melanoma.
Opdivo, Yervoy Combination Study Meets Co-Primary Endpoint americanpharmaceuticalreview
July 26, 2019
Bristol-Myers Squibb announced Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo® (nivolumab) plus low-dose Yervoy® (ipilimumab) met the co-primary endpoint of overall survival (OS) ...
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement worldpharmanews
July 19, 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement.
BMS’ Opdivo fails to reach primary endpoint in HCC pharmaceutical-technology
June 26, 2019
Bristol Myers-Squibb (BMS) has announced that its blockbuster cancer drug Opdivo (nivolumab) has failed to reach its primary endpoint in the Phase III CheckMate-459 trial.
Imfinzi, Opdivo among latest SMC decisions pharmatimes
June 11, 2019
The Scottish Medicines Consortium (SMC) has announced its latest round of medicines for use by NHSScotland, publishing advice accepting five new medicines.
BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme pharmafile
May 16, 2019
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating its efficacy in the treatment of ...
BMS’ Opdivo fails in Phase III glioblastoma trial pharmaceutical-technology
May 13, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy drug Opdivo (nivolumab) has failed to meet its primary endpoint of overall survival (OS) in Phase III CheckMate-498 trial.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page